CRTX:NSD-Cortexyme Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 63.05

Change

0.00 (0.00)%

Market Cap

USD 1.87B

Volume

0.56M

Avg Analyst Target

USD 113.00 (+79.22%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Address: 269 East Grand Avenue, South San Francisco, CA, United States, 94080

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD133.96B 39.21 29.43
BNTX BioNTech SE

N/A

USD60.07B 13.83 10.18
REGN Regeneron Pharmaceuticals Inc

N/A

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD33.45B N/A N/A
SGEN Seagen Inc

N/A

USD31.43B 53.89 40.74
GMAB Genmab A/S

N/A

USD29.05B 74.91 8.12
ALNY Alnylam Pharmaceuticals Inc

N/A

USD24.79B N/A N/A
RPRX Royalty Pharma plc

N/A

USD23.31B 31.09 11.82

ETFs Containing CRTX

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 126.96% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.96% 95% A 95% A
Trailing 12 Months  
Capital Gain 27.45% 72% C- 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.45% 72% C- 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.77% 57% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.77% 57% F 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 47.62% 67% D+ 38% F
Risk Adjusted Return 47.82% 76% C 65% D
Market Capitalization 1.87B 83% B 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 16.42 7% F 7% F
Price / Cash Flow Ratio -36.83 86% B 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -50.01% 58% F 28% F
Return on Invested Capital -54.84% 45% F 15% F
Return on Assets -28.86% 41% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.42 14% F 7% F
Short Percent 14.55% 9% F 11% F
Beta 0.92 71% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.